This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Edwards Lifesciences Corporation, Plasmaselect Gmbh Teterow. Active years: 2000-2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2000-2006
Title: Innovations by Robert Koll in Cardiomyopathy Treatment
Introduction
Robert Koll is an accomplished inventor based in Kirchheim, Germany. He has made significant contributions to the field of medical technology, particularly in the treatment of cardiomyopathy. With a total of 2 patents, his work focuses on innovative methods to improve patient outcomes in cardiac care.
Latest Patents
One of Koll's latest patents addresses the treatment of cardiomyopathy through the removal of autoantibodies. This immunoapheresis treatment involves passing the patient's plasma over a column that has a specific ligand for human immunoglobulin. This process effectively removes a significant portion of the immunoglobulin from the patient's plasma, which is then reinfused back into the patient. The invention utilizes a specific ligand that binds and removes harmful human autoantibodies, such as those against β-adrenergic receptors and myosin heavy chains. The treatment has shown to improve various hemodynamic parameters, including mean arterial pressure and cardiac output.
Another notable patent by Koll focuses on preventing or ameliorating hyperacute or acute rejection of transplanted human organs. This method involves passing the recipient's plasma over a sterile column coupled with anti-human immunoglobulin antibodies. This process binds to and removes a significant portion of the immunoglobulin from the subject's plasma, thereby reducing the risk of organ rejection.
Career Highlights
Throughout his career, Robert Koll has worked with prominent companies in the medical field, including Edwards Lifesciences Corporation and Plasmaselect GmbH Teterow. His experience in these organizations has contributed to his expertise in developing innovative medical treatments.
Collaborations
Koll has collaborated with notable professionals in his field, including Reiner Spaethe and Petra Reinke. These partnerships have further enhanced his research and development efforts in medical technology.
Conclusion
Robert Koll's innovative patents in the treatment of cardiomyopathy and organ rejection demonstrate his commitment to advancing medical science. His work continues to have a significant impact on patient care and treatment methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile